Phreesia (NYSE:PHR) Price Target Cut to $14.00 by Analysts at BMO Capital Markets

Phreesia (NYSE:PHR) had its target price trimmed by BMO Capital Markets from $32.00 to $14.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities analysts have also weighed in on the stock. Citigroup reaffirmed a “neutral” rating and set a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday. Mizuho lowered their price target on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Robert W. Baird restated a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday. Zacks Research cut shares of Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Thirteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.00.

Phreesia Stock Down 27.0%

Phreesia stock opened at $8.33 on Tuesday. The business’s 50-day moving average price is $12.36 and its 200 day moving average price is $17.57. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. Phreesia has a 52 week low of $7.77 and a 52 week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The company had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. During the same period in the previous year, the firm posted ($0.11) earnings per share. The company’s revenue was up 15.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Phreesia will post -1.1 earnings per share for the current year.

Insiders Place Their Bets

In related news, General Counsel Allison C. Hoffman sold 6,585 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the sale, the general counsel owned 174,762 shares of the company’s stock, valued at approximately $2,972,701.62. The trade was a 3.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Balaji Gandhi sold 8,009 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the transaction, the chief financial officer owned 156,231 shares of the company’s stock, valued at $2,657,489.31. This represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 70,358 shares of company stock worth $1,123,569. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

A number of institutional investors and hedge funds have recently modified their holdings of PHR. Granahan Investment Management LLC increased its stake in shares of Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after purchasing an additional 1,018,987 shares in the last quarter. Prosight Management LP purchased a new position in Phreesia in the 4th quarter valued at about $16,533,000. Millennium Management LLC boosted its holdings in Phreesia by 730.7% in the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after buying an additional 936,033 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Phreesia in the 4th quarter worth about $15,213,000. Finally, Greenhouse Funds LLLP increased its stake in Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after buying an additional 557,265 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.